Cencora Inc.
$ 274.91
3.57%
22 May - close price
- Market Cap 53,486,780,000 USD
- Current Price $ 274.91
- High / Low $ 277.39 / 270.88
- Stock P/E 21.05
- Book Value 17.46
- EPS 13.06
- Next Earning Report 2026-08-05
- Dividend Per Share $2.30
- Dividend Yield 0.87 %
- Next Dividend Date 2026-06-01
- ROA 0.03 %
- ROE 1.07 %
- 52 Week High 376.05
- 52 Week Low 244.26
About
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Analyst Target Price
$356.83
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-31 | 2024-05-01 | 2024-01-31 | 2023-11-02 | 2023-08-02 |
| Reported EPS | 4.75 | 4.08 | 3.84 | 4 | 4.42 | 3.73 | 3.34 | 3.34 | 3.8 | 3.28 | 2.86 | 2.92 |
| Estimated EPS | 4.73 | 4.04 | 3.79 | 3.84 | 4.1 | 3.52 | 3.22 | 3.22 | 3.69 | 2.89 | 2.81 | 2.83 |
| Surprise | 0.02 | 0.04 | 0.05 | 0.16 | 0.32 | 0.21 | 0.12 | 0.12 | 0.11 | 0.39 | 0.05 | 0.09 |
| Surprise Percentage | 0.4228% | 0.9901% | 1.3193% | 4.1667% | 7.8049% | 5.9659% | 3.7267% | 3.7267% | 2.981% | 13.4948% | 1.7794% | 3.1802% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 4.37 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-01 | 2026-03-02 | 2025-12-01 | 2025-09-03 | 2025-06-02 | 2025-03-03 | 2024-11-29 | 2024-08-26 | 2024-05-24 | 2024-02-26 |
| Amount | $0.6 | $0.6 | $0.6 | $0.55 | $0.55 | $0.55 | $0.55 | $0.51 | $0.51 | $0.51 |
Next Dividend Records
| Dividend per share (year): | $2.30 |
| Dividend Yield | 0.87% |
| Next Dividend Date | 2026-06-01 |
| Ex-Dividend Date | 2026-05-15 |
Recent News: COR
2026-05-25 20:25:10
Cardinal Health (CAH) has seen strong long-term returns but a recent softer share price, leading investors to re-evaluate its valuation. While the most popular narrative suggests CAH is undervalued at $245.27 compared to its current price of $200.68, other metrics like its P/E ratio indicate it trades at a premium to its sector and peers, suggesting market optimism. Investors are advised to review the company's fundamentals and consider both upside and downside potentials.
2026-05-24 14:25:11
Cardinal Health recently reported an 11% year-on-year revenue increase to US$60.94 billion, missing analyst forecasts for revenue but beating EPS guidance. Management highlighted specialty portfolio growth, stronger free cash flow guidance for fiscal 2026, and ongoing share repurchases as key to its long-term outlook. This article considers how these factors impact Cardinal Health's investment narrative, particularly concerning its capital return strategy and fair value estimate of $245.27 per share.
2026-05-24 11:17:20
Cencora Inc. has appointed its former CEO, Steven Collis, as the new chair of the board shortly after his departure as chief executive. This leadership change follows solid fiscal Q2 results for the pharmaceutical distribution and services group. The article details Cencora's core business model, key revenue drivers, and its significance for US healthcare investors, emphasizing its role in the pharmaceutical supply chain and its exposure to specialty pharmaceuticals and healthcare policy changes.
2026-05-24 09:37:17
The provided content is extremely limited, containing only the title and publisher name. No comprehensive summary can be generated without the full article text.
2026-05-24 01:32:59
McKesson's oncology insights business, Ontada, has partnered with Florida Cancer Specialists & Research Institute to expand its real-world oncology data platform. This move highlights McKesson's strategic focus on data-driven services alongside its core distribution business, especially as oncology remains a critical area in healthcare. While the partnership strengthens McKesson's position in cancer care services, investors are also weighing the company's valuation, which Simply Wall St describes as trading at a significant premium to its estimated fair value.
2026-05-22 21:37:19
Cencora Inc (COR) shares recently rose by 3.6% to $274.91, despite an 18.3% year-to-date decline. GuruFocus assesses the stock as 5.4% undervalued compared to its GF Value™ of $290.62, giving it a GF Score™ of 79/100, indicating high overall quality with strong valuation. However, there has been no insider activity in the last three months, and its momentum score is moderate.
